Newly diagnosed HFpEF in patients with atrial fibrillation: prevalence and impact on antiarrhythmic and antithrombotic management

14 March 2025 (08:45 - 18:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Washington Villon

Hospital Alcivar Guayaquil, Guayaquil (Ecuador)

5 More presentations in this session

Presentation thumbnail

Clinical impact of inappropriate DOAC dosing in atrial fibrillation: insights from a real-world registry

Doctor M. Yildirim (Heidelberg, DE)

Abstract Slides

Presentation thumbnail

Electrical cardioversion of long-standing persistent atrial fibrillation: the importance of antiarrhythmic pretreatment

Doctor S. Andraz (Faro, PT)

Abstract Slides

Presentation thumbnail

Importance of immediate bystander life support on short and long-term survival of patients with out-of-hospital cardiac arrest and myocardial infarction

Associate Professor A. Aleksova (Trieste, IT)

Abstract Slides

Presentation thumbnail

Primary ventricular fibrillation epidemic in the STEMI Code era. Trends and acute-phase mortality over the last 15 years

Doctor C. Garcia-Garcia (Barcelona, ES)

Abstract Slides

Presentation thumbnail

Taming ventricular tachycardia: experience of stellate ganglion ablation across the spectrum of ventricular arrhythmias, a safe and effective intervention beyond the electrical storm

Doctor J. Larre Guerra (Madrid, ES)

Abstract Slides

Access the full session

Session thumbnail

Arrhythmias in acute cardiac care

The Event

Event poster

ESC Acute CardioVascular Care 2025

14 March - 15 March 2025

You may be interested in

Congress Presentation

Interactive discussion and Q&A

Congress Session

Treatment strategies for atrial fibrillation in heart failure

Congress Session

EHRA Myths - Device-detected atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources